Teva Pharmaceutical will now stop developing migraine drug Ajovy (fremanezumab) as a treatment for cluster headaches. This comes after the drugmaker realized it was not likely to meet the goal of a late-stage trial.
The drug was approved as a prevention for migraines in September. It is still being as a treatment for post-traumatic headache.
Ajovy is competing with treatments from Eli Lilly and Amgen, which includes a treatment from the former that received breakthrough status from the U.S. Food and Drug Administration.
Read the Reuters report